Marsh & McLennan Companies (MRSH) is trading near $187 per share, having rebounded from a September decline that took the stock below $170. The recovery gained momentum in mid-October when the firm delivered third-quarter results that exceeded expectations, with shares jumping roughly 4.7% in a single session. As a diversified professional-services business spanning insurance brokerage, reinsurance, benefits, and consulting, the company is widely followed as a bellwether for corporate risk-management spending and global insurance pricing trends. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Marsh & McLennan is a global leader in risk, strategy, and people, operating through two primary segments: Risk and Insurance Services and Consulting. The firm's four core businesses—Marsh (insurance brokerage), Guy Carpenter (reinsurance), Mercer (health, wealth, and career consulting), and Oliver Wyman (management consulting)—each hold leading positions in their respective markets, serving clients in more than 130 countries.
The company's competitive strength lies in its scale, deep industry expertise, and diversified revenue base, which spans insurance placement, reinsurance broking, benefits administration, asset management, and strategy consulting. Notably, the firm completed a corporate rebranding to "Marsh" and adopted the MRSH ticker symbol effective January 14, 2026, consolidating its identity around its flagship brokerage brand. Investors follow the stock for its consistent organic growth, disciplined capital returns through dividends and buybacks, and resilient earnings profile across economic cycles.
The most significant recent catalyst was the company's third-quarter 2026 earnings release, which reported 8% revenue growth to $6.9 billion and a 10% year-over-year increase in adjusted EPS to $2.03. Management Consulting stood out with 14% underlying growth, reflecting strong demand for AI-related advisory services and successful execution of digital initiatives.
Investors also responded favorably to the increase in the company's Thrive cost-transformation savings target from $400 million to $600 million, alongside stated intentions to reinvest those savings into sales, technology, and capabilities. Share repurchases totaled $500 million in the quarter and $2 billion year to date, underscoring management's confidence in cash generation.
Offsetting these positives, reinsurance revenue declined 6% amid soft market conditions, and global insurance rates fell 5% during the quarter—with property rates down 10%—pressuring brokerage commissions. The company also recorded $144 million in litigation costs tied to Greensill, which weighed on notable items and overall profitability. From what I see, these offsets are worth monitoring closely.
Looking ahead, several factors will shape MRSH's trajectory through the remainder of 2026. Management flagged that fiduciary interest income, which declined $9 million year over year in the third quarter, is expected to fall further in the fourth quarter. Reinsurance conditions and global insurance-rate trends—particularly property pricing—will remain important variables for brokerage revenue growth.
On the positive side, continued momentum in AI-related consulting demand, the expanded Thrive savings program, and a robust mergers-and-acquisitions pipeline (with $288 million deployed on acquisitions in the quarter) offer potential upside. Investors should monitor upcoming earnings guidance, the pace of share repurchases, integration of recent acquisitions, and any further developments in the Greensill litigation, alongside broader macroeconomic conditions affecting corporate insurance spending. I’m watching this closely as the year wraps up.
When reviewing price action and potential signals for names like this, I often turn to Tickeron’s Trending AI Robots page. It highlights a curated selection of algorithmic trading bots that cover thousands of tickers, with only the top-performing and most relevant ones featured. The bots span different strategies, timeframes, and performance metrics, which helps me explore approaches ranging from short-term momentum to longer-horizon trend following in a systematic way.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Indicator for MRSH moved out of overbought territory on November 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 instances where the indicator moved out of the overbought zone. In 17 of the 33 cases the stock moved lower in the days that followed. This puts the odds of a move down at 52%.
The Moving Average Convergence Divergence Histogram (MACD) for MRSH turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 25 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRSH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.
MRSH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 57 cases where MRSH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on MRSH as a result. In 48 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
MRSH moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MRSH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 33%.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRSH advanced for three days, in 164 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.
The Aroon Indicator entered an Uptrend today. In 91 of 263 cases where MRSH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 35%.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MRSH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.438) is normal, around the industry mean (2.794). P/E Ratio (24.948) is within average values for comparable stocks, (19.877). Projected Growth (PEG Ratio) (1.486) is also within normal values, averaging (8.322). Dividend Yield (0.019) settles around the average of (0.042) among similar stocks. P/S Ratio (3.089) is also within normal values, averaging (3.106).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry InsuranceBrokersServices